Zofran Side Effects - Oral Clefts and Heart Defects Lawsuit

Zofran Birth Defect Lawsuits

Start Claim Now

Pregnant women who take Zofran to treat morning sickness may have an increased risk of giving birth to babies with severe birth defects including cleft lip, cleft palate and heart defects.

birth injuryPlenty of women experiencing severe bouts of nausea and vomiting may turn to anti-nausea medications like Zofran to relieve their symptoms. However, recent studies have shown that the popular anti-nausea drug Zofran, which is commonly promoted off-label by GlaxoSmithKline as a treatment for morning sickness in pregnant women, may actually be linked to an increased risk of severe birth defects in babies exposed to the medication in utero. If you believe your child has been adversely affected by an alleged Zofran birth defect, our consumer advocates at the Consumer Justice Foundation can help. We are dedicated to protecting the rights of consumers harmed by potentially dangerous medications, and can help put you in touch with a reputable Zofran lawyer who has experience handling birth defect claims.

Zofran Alternatives for Morning Sickness during Pregnancy

The management of nausea and vomiting during pregnancy depends on the severity of the symptoms, but some possible alternative treatments include:

  • Dietary changes – Eating frequent, small meals; sticking to bland-tasting solid foods that are high in carbohydrates and low in fat; eating salty foods earlier in the morning; choosing sour and tart liquids (like lemonade) over water in some cases.
  • Acupressure – Numerous studies have shown that acupressure may be successful in treating nausea in some cases, and may help control morning sickness in early pregnancy.
  • Ginger – In the form of ginger tea, ginger ale, in capsule form and in preserves, ginger is a popular alternative treatment for morning sickness, and one European study found that ginger powder was more effective than a placebo in reducing the symptoms of hyperemesis gravidarum.

What is Zofran?

Zofran (ondansetron) is a 5-HT3 receptor antagonist anti-nausea medication commonly prescribed off-label to pregnant women suffering from Hyperemesis gravidarum, a severe form of morning sickness often described as unrelenting, excessive pregnancy-related nausea and/or vomiting that prevents sufficient intake of fluids and food. The drug was approved by the FDA in 1991, and is currently manufactured by pharmaceutical giant GlaxoSmithKline. However, recent studies have established a potential connection between the use of Zofran during pregnancy and an increased risk of heart defects, cleft lip, cleft palate and other devastating birth defects among babies exposed to the drug in utero.

Possible Side Effects of Zofran

Despite the fact that Zofran has been on the market in the United States for more than 20 years, it was only recently that studies began to examine the possible risk of birth defects among babies exposed to the morning sickness drug during pregnancy. Among the birth defects possibly linked to Zofran use in pregnant women are:

  • Cleft lip
  • Cleft palate
  • Heart defects
  • Atrial septal defect
  • Ventricular septal defect
  • Heart murmur
  • Kidney malformations
  • Mouth deformities
  • Musculoskeletal malformations
  • Fetal growth restriction
  • Fetal death

The FDA has categorized Zofran is a pregnancy Category B medication, which means there is no adequate or well-controlled research examining the safety of Zofran use in pregnant women. However, a growing body of research has demonstrated the potential adverse effects Zofran can have on a developing fetus.

Zofran Lawsuits and Settlements

May 27, 2015 – An Arkansas woman whose baby was born with a cleft lip after being exposed to Zofran during pregnancy filed a lawsuit against GSK for failing to warn about the risk of birth defects from Zofran.

May 22, 2015 – A California woman filed a birth defect lawsuit against GSK after taking Zofran while pregnant and giving birth to a baby with supraventricular tachycardia, a heart rhythm disorder characterized by shallow breathing, rapid breathing and shortness of breath.

April 24, 2015 – A federal lawsuit was brought against GSK by a woman in Massachusetts who took Zofran while pregnant, and was forced to terminate her pregnancy after her baby developed life-threatening abdominal birth defects.

April 22, 2015 – A Texas woman filed a federal lawsuit against GSK, alleging that the company’s anti-nausea drug Zofran caused her child to be born with a number of birth defects, including developmental delays, brain abnormalities and heart malformations.

April 6, 2015 – A lawsuit was filed against GSK by the family of a boy in Alabama who was born with severe chromosomal birth defects after his mother took Zofran while pregnant.

April 3, 2015 – The parents of a child in Montana born with oral cleft birth defects after being exposed to Zofran in pregnancy filed a lawsuit against GSK for failing to warn consumers and the medical community about the risk.

February 23, 2015 – A woman from Minnesota whose two children suffered from heart defects after being exposed to Zofran in pregnancy filed a lawsuit against GSK.

February 19, 2015 – A lawsuit was filed against GSK after a woman from Massachusetts who took Zofran while pregnant gave birth to a baby with three heart defects, webbed toes, facial deformities and a number of other birth defects.

August 2012 – The Justice Department filed a lawsuit against GSK, accusing the company of illegally marketing Zofran off-label as a treatment for pregnant women with morning sickness, in violation of federal law. GSK was ordered to pay $3 billion to resolve these claims.

FDA, Zofran and Birth Defects

The FDA has not issued specific warnings about the use of Zofran in pregnancy, despite the growing body of research linking the anti-nausea drug to an increased risk of serious birth defects, which could pose a serious problem for women with electrolyte imbalances due to severe morning sickness, or hyperemesis gravidarum. The following are the actions the FDA has taken to warn consumers and the medical community about the risk of Zofran side effects:

  • December 2, 2012 – The FDA issues a Drug Safety Communication indicating that the 32 mg, single intravenous dose of Zofran will no longer be marketed, due to the potential for the drug to cause serious cardiac risks.
  • June 29, 2012 – The FDA issues a warning regarding the risk of QT prolongation from Zofran, indicating that use of intravenous Zofran may affect the electrical activity of the heart, possibly leading to a potentially fatal condition known as Torsades de Pointes.
  • September 15, 2011 – The FDA issues a warning about the risk of abnormal heart rhythms associated with the use of Zofran, possibly leading to Torsades de Pointes.

Zofran Birth Defect Studies

September 2004 – A study published by the medical journal BJOG: an International Journal of Obstetrics and Gynaecology found case reports tying Zofran to a risk of hypospadias birth defects, but this alleged risk was never investigated by GSK. Hypospadias is a serious birth malformation in boys characterized by a urethral opening that is located somewhere other than at the tip of the penis. The condition almost always requires surgery, and without treatment, boys born with hypospadias may be forced to urinate sitting down, and may suffer from sexual dysfunction later in life.

November 2011 – A study published by Birth Defects Research found that the use of Zofran in pregnancy to treat nausea and vomiting associated with morning sickness, was associated with a 2.4-fold increased risk of cleft palate birth defects in babies.

January 2012 – In a study based on data from approximately 9,000 pregnant women who participated in the National Birth Defects Prevention Study, researchers found a 2.4-fold increased risk of cleft palate among babies whose mothers took Zofran while pregnant.

February 2013 – The New England Journal of Medicine published a study indicating that Zofran did not increase the risk of birth defects in babies. However, half of the women involved in the study took Zofran after the 10th week of pregnancy, at which point babies have a lower risk of suffering birth defects like heart malformations, cleft lip and cleft palate. Research has shown that unborn babies face the highest risk of birth defects during the first trimester, a time when many women aren’t even aware they are pregnant, and a number of other studies have disputed these NEJM results.

August 2013 – Six months after the NEJM study was published, another team of researchers conducted another study analyzing the same pregnancy data, and found that Zofran increased a baby’s risk of birth defects by 30%, and doubled their risk of heart defects.

December 2014 – One study published in the journal Reproductive Toxicology found that use of Zofran during the first trimester of pregnancy doubled the risk of “hole in the heart” birth defects like atrial septal defects and ventricular septal defects. Overall, the risk of heart defects among babies exposed to Zofran in pregnancy was 62% higher than normal.

December 2014 – An investigation by the Toronto Star indicated that Zofran has been linked to a number of instances of birth defects in babies, including: two fetal deaths, multiple reports of kidney malformations, intrauterine growth restriction in six infants, musculoskeletal abnormalities, and one baby’s mouth deformity, heart murmur, jaundice and two heart defects.

March 2015 – A study published in Pediatric Emergency Care highlights two instances where children died from heart problems after being given ondansetron, the active ingredient in Zofran.

Why We Think GlaxoSmithKline Should Be Held Liable for Zofran Birth Defects

Untitled-1According to court documents, GlaxoSmithKline knew as early as 1992 that Zofran was capable of passing through the human placenta and presenting an “unreasonable risk of harm” to developing babies in the womb. Despite this knowledge, GlaxoSmithKline continued to promote the drug as a treatment for morning sickness in pregnant women, and Zofran lawsuits brought against the drug maker allege the following:

  • GlaxoSmithKline manufactured a defective drug
  • GSK had a duty to ensure Zofran was safe before selling it to consumers, and failed to provide the public with adequate warnings about the alleged risk of Zofran birth defects
  • GSK failed to evaluate all data and safety information regarding the use of Zofran during pregnancy
  • GSK marketed Zofran as a safe treatment for morning sickness, even though it wasn’t approved by the FDA for this use
  • GSK falsely and fraudulently claimed that Zofran was safe for use among pregnant women
  • GSK claimed that animal studies showed Zofran was safe, when the results actually indicated abnormal bone growth and signs of toxicity

What should you do? If your child was born with an oral cleft or a heart defect you should contact a lawyer as soon as possible to discuss filing a Zofran birth defect lawsuit.

The potential for Zofran to cause birth defects in unborn babies is particularly alarming because women of childbearing age may take the controversial drug to combat nausea or vomiting without realizing they are pregnant and may be exposing their unborn baby to serious harm. If you took Zofran while pregnant, and your child has been diagnosed with a severe birth defect like cleft lip, cleft palate, fetal growth restriction or a heart malformation, contact a knowledgeable Zofran attorney today for legal help. You may have grounds to file a Zofran lawsuit against GlaxoSmithKline, in order to pursue financial compensation for your child’s birth defects, pain and suffering, and current and future medical expenses.

Start Claim Now
Do you deserve compensation?

An attorney will review your situation for FREE and help you found out what really went wrong.

How Can We Reach You?

Please Explain Your Situation

By clicking the "Submit" button below, you agree that law firms you are matched with may contact you by telephone even if you are on a federal or state Do Not Call registry. Up to 10 law firms may respond to your request within approximately 2 weeks. In some cases 3 or more firms may respond to your request after 30 days. Use of this site is subject to our Terms of Use.